We also utilized another risk model for advanced UC patients treated with pembrolizumab previously reported by Yamamoto et al. using four factors (ECOG-PS ≥ 2, without only lymph node metastasis, CRP > 0.56 mg/dL, and an NLR > 3.0 at the initiation of pembrolizumab treatment) [10]. Here, CRP is linked to metastatic malignant neoplasm in the lymph nodes.